Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Improved small animal Positron Emission Tomography (PET) scanners introduced by IntelLiDrives

In research into human diseases and the search for potential treatments, small animal models play an important role in bridging the gap between in vitro and in vivo studies. IntelLiDrive is at the forefront of small animal PET tomography scanner design.

5 Oct 2012

New prototype mouse model duplicates the human response in rheumatoid arthritis

Researchers at Northwestern University Feinberg School of Medicine have developed the first animal model that duplicates the human response in rheumatoid arthritis (RA), an important step that may enable scientists to discover better medicines to treat the disease.

5 Oct 2012

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting. The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way.

5 Oct 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

MiR-214 plays a critical role in regulating ovarian cancer stem cell properties

Researchers at Moffitt Cancer Center have discovered that the micro ribonucleic acid miR-214 plays a critical role in regulating ovarian cancer stem cell properties. This knowledge, said the researchers, could pave the way for a therapeutic target for ovarian cancer.

28 Sep 2012

Researchers identify several kinase inhibitors that help generate many iPSCs

The process researchers use to generate induced pluripotent stem cells (iPSCs)-a special type of stem cell that can be made in the lab from any type of adult cell-is time consuming and inefficient. To speed things up, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) turned to kinase inhibitors.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Sarawak Biodiversity Centre in Malaysia, OSU to develop and commercialize anticancer agent

The Ohio State University has signed an agreement with the Sarawak Biodiversity Centre in Malaysia to collaborate on the further development and commercialization of a promising anticancer agent derived from a tropical tree that grows on the island of Borneo.

25 Sep 2012

Thomson Reuters names Sanford-Burnham cancer researcher among 2012 Citation Laureates

Thomson Reuters has selected Erkki Ruoslahti, M.D., Ph.D., cancer researcher and distinguished professor at Sanford-Burnham Medical Research Institute (Sanford-Burnham), as one of its 2012 Citation Laureates. Citation Laureates are scientists that Thomson Reuters has predicted to win the Nobel Prize.

24 Sep 2012

RTI International receives NIH contract to serve as regional metabolomics research core center

RTI International has been awarded a five-year contract from the National Institutes of Health to serve as a regional comprehensive metabolomics research core center.

24 Sep 2012

Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Vanderbilt University and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson's disease.

21 Sep 2012

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

Investigators at Northwestern University Feinberg School of Medicine have identified two promising therapies to treat patients with acute megakaryocytic leukemia (AMKL), a rare form of leukemia where the number of cases is expected to increase with the aging population.

21 Sep 2012

ChanTest announces Phase II SBIR grant to optimize cardiomyocyte-based assays

ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes

18 Sep 2012

MediSapiens launches unified cloud computing application for personalized genomics

MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics.

17 Sep 2012

Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria.

15 Sep 2012

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

The Neurodegeneration Consortium (NDC), a transformative multi-institutional initiative, will advance the study and treatment of Alzheimer's and other neurodegenerative diseases, thanks to an inaugural $25 million gift from the Robert A. and Renee E. Belfer Family Foundation to The University of Texas MD Anderson Cancer Center, Baylor College of Medicine and the Massachusetts Institute of Technology (MIT).

13 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

Stanford and MBL scientists win prestigious Lasker Awards

Scientists who invented new ways to study how "cargo" is moved within cells and, as a result, discovered a new biological motor protein, kinesin, at the Marine Biological Laboratory (MBL) in Woods Hole, Mass., have received the prestigious 2012 Lasker Award for Basic Medical Research, the Albert and Mary Lasker Foundation announced today.

11 Sep 2012

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

10 Sep 2012

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

SPT Labtech will be offering delegates at MipTec 2012 (24th-27th September, Basel, Switzerland) the opportunity to experience their innovative automated solutions for effortless drug discovery first-hand.

From SPT Labtech 7 Sep 2012

Drug Discovery News and Research

Further Reading

Improved small animal Positron Emission Tomography (PET) scanners introduced by IntelLiDrives

New prototype mouse model duplicates the human response in rheumatoid arthritis

Countering neuroinflammation is indeed a potential therapeutic strategy for Alzheimer's

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

MiR-214 plays a critical role in regulating ovarian cancer stem cell properties

Researchers identify several kinase inhibitors that help generate many iPSCs

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Sarawak Biodiversity Centre in Malaysia, OSU to develop and commercialize anticancer agent

Thomson Reuters names Sanford-Burnham cancer researcher among 2012 Citation Laureates

RTI International receives NIH contract to serve as regional metabolomics research core center

Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Investigators identify two promising therapies to treat patients with acute megakaryocytic leukemia

ChanTest announces Phase II SBIR grant to optimize cardiomyocyte-based assays

MediSapiens launches unified cloud computing application for personalized genomics

Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

NDC to advance study and treatment of Alzheimer's and other neurodegenerative diseases

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

Stanford and MBL scientists win prestigious Lasker Awards

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

Drug discovery solutions from SPT Labtech to be demonstrated at MipTech

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News